Figure 4.

Pharmacokinetic profile of mean (±SEM) fospropofol and propofol concentrations in plasma following administration of fospropofol to human subjects by PO, IV and ID routes. A single dose of 400 mg was administered to seven volunteers in a sequential crossover design. Almost no plasma fospropofol was detected when administered by any non-intravenous route (a). In contrast, propofol bioavailability from fospropofol was substantial, ranging between 34 and 48% respectively by AUC (b). Data shown as mean ± SEM.